ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Pauling.AI Announces Launch of Fully Automated Drug Discovery Agent for Small Molecules

By: Prodigy
10/06/2025, Boston, MA // PRODIGY: Feature Story //

Pauling.AI, an AI-first biotech company, today announced the launch of its fully automated drug discovery agent for small molecules. The agent orchestrates end-to-end in-silico workflows, including target ingestion, molecular generation and screening, docking, molecular dynamics, and ADMET prediction, so scientists can move from hypothesis to testable candidates dramatically faster and at lower cost. Pauling.AI aims to build the best possible AI drug discovery workflow.

“AI agents should feel like a world-class computational chemist that never sleeps,” said Javier Tordable, Founder & CEO of Pauling.AI and a former Google technology leader. “By automating the heavy lifting (simulation, triage, and documentation) we let teams focus on the science that matters: choosing the right biology and advancing the best molecules.”

Pauling.AI builds AI agents that automate drug discovery.
Pauling.AI

Early materials describe Pauling.AI as “the AI chemist that automates drug discovery,” highlighting autonomous workflows for docking and simulation, and positioning the platform to help startups go from idea to testable molecule in less than a week. The company participates in the NVIDIA Inception program and lists Google for Startups among supporters.

Agentic systems are emerging across pharma, Pauling.AI’s launch focuses currently on small-molecule programs and emphasizes turnkey automation over point tools, integrating generation, physics-based evaluation, and developability checks in one loop.

Availability

Pauling.AI’s fully automated small-molecule agent is available today to selected biotech and pharma partners. Teams interested in pilots can inquire via the company’s website. pauling.ai

About Pauling.AI

Pauling.AI builds AI agents that automate drug discovery. Headquartered in Boston, MA, the company’s platform compresses early discovery timelines by automating computational chemistry and in-silico candidate triage. Pauling.AI is led by Javier Tordable (ex-Google) and is a member of NVIDIA Inception.

###

Media Contact:

info@pauling.ai 

pauling.ai





newsroom: news.38digitalmarket.com



Source: 38 Digital Market News

Release ID: 1846118

Source published by Submit Press Release >> Pauling.AI Announces Launch of Fully Automated Drug Discovery Agent for Small Molecules


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.